University of Utah, ARUP Laboratories
Salt Lake City, UT
Fellowship - Medical Microbiology
2009
University of Illinois
Chicago, IL
Residency - AP/CP Pathology
2008
University of Belgrade School of Medicine
Serbia
MS - Medical Microbiology
1997
University of Belgrade School of Medicine
Serbia
Residency - Medical Microbiology
1996
University of Belgrade School of Medicine
Serbia
MD - Medicine
1990
Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more.
Novel paradigm enables accurate monthly gestational screening to prevent congenital toxoplasmosis and more. PLoS Negl Trop Dis. 2024 May; 18(5):e0011335.
PMID: 38805559
Expect the unexpected: endocarditis caused by Legionella feeleii.
Expect the unexpected: endocarditis caused by Legionella feeleii. Lab Med. 2024 May 23.
PMID: 38780098
Performances of ICT Toxoplasma IgG-IgM test in comparison with Vidas® toxo competition to determine the immune status against Toxoplasma gondii.
Performances of ICT Toxoplasma IgG-IgM test in comparison with Vidas® toxo competition to determine the immune status against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 2023 Nov; 42(11):1327-1335.
PMID: 37749274
Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview.
Building Programs to Eradicate Toxoplasmosis Part I: Introduction and Overview. Curr Pediatr Rep. 2022; 10(3):57-92.
PMID: 36034212
Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances "Take a Village".
Building Programs to Eradicate Toxoplasmosis Part IV: Understanding and Development of Public Health Strategies and Advances "Take a Village". Curr Pediatr Rep. 2022; 10(3):125-154.
PMID: 35991908
Building Programs to Eradicate Toxoplasmosis Part II: Education.
Building Programs to Eradicate Toxoplasmosis Part II: Education. Curr Pediatr Rep. 2022 Sep; 10(3):93-108.
PMID: 36969368
Building Programs to Eradicate Toxoplasmosis Part III: Epidemiology and Risk Factors.
Building Programs to Eradicate Toxoplasmosis Part III: Epidemiology and Risk Factors. Curr Pediatr Rep. 2022 Sep; 10(3):109-124.
PMID: 37744780
Evaluating specimen pooling for Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium screening in asymptomatic men who have sex with men.
Evaluating specimen pooling for Neisseria gonorrhoeae, Chlamydia trachomatis, and Mycoplasma genitalium screening in asymptomatic men who have sex with men. Int J STD AIDS. 2022 07; 33(8):761-765.
PMID: 35610756
Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer.
Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer. Am J Clin Pathol. 2022 01 06; 157(1):109-118.
PMID: 34463315
Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer.
Chan CW, Yi X, Lenza M, Baldwin AD, Jakalski J, Tesic V, Yeo KJ. Analytical and Clinical Evaluation of the Semiquantitative Elecsys Anti-SARS-CoV-2 Spike Protein Receptor Binding Domain Antibody Assay on the Roche cobas e602 Analyzer. Am J Clin Pathol. 2021 Aug 31.
PMID: 34463315